India has obvious advantages in Biogenerics development and if these advantages are exploited to its favor then India does have the potential to become a major Biogenerics Hub. Some of the advantages that India enjoys are:

1) India offers a diverse pool of gene pool and disease profiles. It is difficult to match the biodiversity available in India

2) India has the advantage of availability of cells and tissues from in vitro fertilization clinics coupled with scientific brains and Information technology talent.

3) Low operational cost and capital requirement for Bio Manufacturing.

4) Presence and excellence in different areas related to Biogenerics.

Market Drivers

1) There are about two dozen biologics that are likely to go off patent in United States by 2010, some of which are blockbusters.

2) Overall drug demand for Biogenerics for aging population in the large markets.

3) Entry of Biogenerics products in unexplored markets in Europe and US.

4) Low prices of Biogenerics products have potential to increase demand significantly, which was restrained because of high prices of branded products.

5) Governments support for biotech industry

Market Restraints

1) Availability of Biogenerics products in unregulated and semi regulated markets.

2) Complex regulatory approval processes and patent issues.

3) Hesitance to use of bio generic products

4) There are Intellectual property issues which can slow down development of Biogenerics.

Competitive Position: India/Indian Companies

India and Indian companies should be in a comfortable position regarding their place in the Biogenerics market in future. With vast export potential in the field of Biogenerics there have been quite a few companies who have made their name in the market and should continue to do so. There are more and more partnerships and outsourcing happening in the space of Biogenerics and allied fields.

The positives being on their side, the Indian companies need to retain reverse engineering capability and process chemistry along with full integration and regulatory compliance.

A bright future for Indian Biotech Industry lies ahead, it